SARS-CoV-2 NeutraLISA by EUROIMMUN

Manufacturer EUROIMMUN  |  Available Worldwide
The SARS-CoV-2 NeutraLISA provides fast and economical determination of the inhibiting effect of anti-SARS-CoV-2 antibodies in patient samples, serving as a surrogate virus neutralisation test. The assay is based on competitive binding between neutralising antibodies in the samples and labelled ACE2 receptors to S1/RBD. The test supports evaluation of the immune response following SARS-CoV-2 infection or vaccination.


SARS-CoV-2 NeutraLISA by EUROIMMUN product image
SARS-CoV-2 NeutraLISA
Request Pricing

Receive your quote directly from the manufacturer.



0 Scientists have reviewed this product


Write the First Review

No Reviews

  • Surrogate virus neutralisation test (sVNT) for determination of neutralising antibodies that inhibit the binding of SARS-CoV-2 S1/RBD to ACE2 receptors 
  • Very good (98.6%) agreement of results in comparison with the plaque reduction neutralisation test (PRNT50)
  • Established ELISA method –suitable for routine diagnostics, no BSL-3 conditions required 
  • Automatable even for high-throughput analyses, results available in 2 hours
  • CE marked
     

Product Overview

SARS-CoV-2 NeutraLISA by EUROIMMUN product image

SARS-CoV-2 NeutraLISA

Manufacturer EUROIMMUN  |  Available Worldwide

Be the first to review this product